Authors: A.I. Archakov¹, A.P. Selzovskyi², V.I. Lisov³, D.I. Zyganov⁴, V.A. Knyazhev⁵, O.M. Ipatova¹, T.I. Torkhovskaya¹

Address:

¹ Orekhovich Institute of Biomedical Chemistry, Pogodinskaya, 10, Moscow

² Public Health Committee of Moscow Government

³ Education Committee of Moscow Government

⁴ Moscow Committee on Science and Technology

⁵ Ministry on Industry, Science and Technology of Russian Federation

Abstract:

The review summarizes the results of long term study (from design to clinical trial) of a new hepatoprotective drug Phosphogliv. Some theoretical ground for its creation has been considered with spetial emphasis on its ingredient properties: soy bean phosphatidylcholine and glycyrrhizinic acid from licorice roots. Experimental and clinical data   concerning polyene phosphatidylcholine repairing action on cell membranes as well as antiviral and immunomodulating effects of glycyrrhizinic acid are presented. Their selected combination  in Phosphogliv  provided  its high efficiency  in rat hepatitis models. After standard toxicology tests it was allowed to carry out the clinical trials of this preparation in the treatment of liver diseases patients – mainly with acute and chronic viral hepatitis B, C, A and mixed hepatitis B+C (total 203 patients).  The inclusion of Phosphogliv into therapy coarse accelerated disappearance of intoxication symptoms and decrease of serum aminotransferase and other hepatic markers. The effect was more pronounced  for  intravenous drug form.

Key  words: phosphatidylcholine, glycyrrhizinic acid, hepatitis, liver, biomembranes.

[Back]